Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novocure Ltd Ord Sh
(NQ:
NVCR
)
17.90
-1.01 (-5.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novocure Ltd Ord Sh
< Previous
1
2
3
4
5
6
7
Next >
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
August 14, 2024
From
Novocure
Via
Business Wire
Novocure Reports Second Quarter 2024 Financial Results
July 25, 2024
From
Novocure
Via
Business Wire
Novocure to Report Second Quarter 2024 Financial Results
July 01, 2024
From
Novocure
Via
Business Wire
NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain
January 18, 2024
Via
Investor Brand Network
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
June 03, 2024
From
Novocure
Via
Business Wire
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
May 02, 2024
From
Novocure
Via
Business Wire
Novocure Reports First Quarter 2024 Financial Results
May 02, 2024
From
Novocure
Via
Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
April 24, 2024
From
Novocure
Via
Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024
From
Novocure
Via
Business Wire
Novocure to Report First Quarter 2024 Financial Results
April 01, 2024
From
Novocure
Via
Business Wire
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 27, 2024
From
Novocure
Via
Business Wire
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
March 11, 2024
From
Novocure
Via
Business Wire
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
February 22, 2024
From
Novocure
Via
Business Wire
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
January 18, 2024
From
Novocure
Via
Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
January 09, 2024
From
Novocure
Via
Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
January 08, 2024
From
Novocure
Via
Business Wire
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
January 04, 2024
From
Novocure
Via
Business Wire
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Novocure
Via
Business Wire
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
November 28, 2023
From
Novocure
Via
Business Wire
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
November 21, 2023
From
Novocure
Via
Business Wire
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
November 10, 2023
From
Novocure
Via
Business Wire
Novocure Reports Third Quarter 2023 Financial Results
October 26, 2023
From
Novocure
Via
Business Wire
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
October 15, 2023
From
Novocure
Via
Business Wire
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
October 12, 2023
From
Novocure
Via
Business Wire
NovoCure Limited (NASDAQ:NVCR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
October 10, 2023
San Diego, CA -- (SBWIRE) -- 10/10/2023 -- An investigation was announced for investors in shares of NovoCure Limited (NASDAQ:NVCR) concerning potential breaches of fiduciary duties by certain...
Via
SBWire
Novocure to Report Third Quarter 2023 Financial Results
October 02, 2023
From
Novocure
Via
Business Wire
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
September 29, 2023
From
Novocure
Via
Business Wire
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
September 08, 2023
From
Novocure
Via
Business Wire
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
August 29, 2023
From
Novocure
Via
Business Wire
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
August 28, 2023
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.